BUZZ-EyePoint Pharma rises on eye disease drug trial data

Shares of drugmaker EyePoint Pharmaceuticals EYPT.O rise ~11% to $8.47

EYPT says its drug, Duravyu, met the main goal in mid-stage trial for the treatment of diabetic macular edema, a condition where fluid builds up in the central part of the retina due to damaged blood vessels

The main goal was to evaluate if the drug could reduce the frequency of injections needed to treat the condition compared to the standard treatment, aflibercept

2.7 mg dose of Duravyu helped 73% of patients avoid extra injections, compared to 50% of patients treated with aflibercept - EYPT

Co plans to initiate a late-stage non-inferiority trial for the drug by the end of 2025

EYPT fell ~67% in 2024